NCT07112612View on ClinicalTrials.gov

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

April 30, 2027

Conditions
MRDProstate CancermHSPC
All Listed Sponsors
lead

Anhui Medical University

OTHER